57095-07-5Relevant academic research and scientific papers
Synthesis, characterization and solvatochromism investigation of mixed ligand chelate copper(II) complexes with acetyleacetonate and three diamine ligands
Golchoubian, Hamid,Afshar, Zahra Mohseni,Moayyedi, Golasa,Bruno, Giuseppe,Rudbari, Hadi Amiri
, p. 1873 - 1880 (2012)
The syntheses of three mixed ligand chelate copper(II) complexes of the type [Cu(L)(acac)(H2O)]BPh4 where acac=acetyleacetonate; L=N,N-dimethyl,N′-benzylethane-1,2-diamine (L1), N,N-dimethyl, N′-2-methylbenzylethane-1,2-diamine (L2) or N,N-dimethyl,N′-2-chlorobenzylethane-1,2-diamine (L3) are reported and characterized by elemental analyses, spectroscopic and molar conductance measurements. The X-ray structure of complex 1 shows that the central copper atom is placed in a distorted square pyramidal geometry made by acac and diamine chelate in the base and a H2O molecule on the apex. The prepared complexes are fairly soluble in a large number of organic solvents and show positive solvatochromism. Calculations of SMLR (stepwise multiple linear regression) method was utilized to find the best model explaining the observed solvatochromic behavior and showed that among different solvent parameters, donor number (DN) is a dominant factor responsible for the shift in the d-d absorption band of the complexes to the lower wavenumber with increasing its values. The importance of substituent effect in diamine ligand on the spectral and SMLR measurements is also discussed.
CXCR7 RECEPTOR MODULATORS
-
Page/Page column 113; 114, (2016/06/28)
The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
TACHYKININ RECEPTOR ANTAGONISTS
-
Page 29, (2010/02/10)
The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
